TOP HEADLINES

Featured Story

UCL taps Elsevier resource to advance drug repurposing research

UCL has made Elsevier's PharmaPendium available to its researchers. The United Kingdom academic institution has subscribed to the resource to support its staffers' research into drug repurposing and the personalization of treatments.

U.K. starts enrolling cancer patients into the 100,000 Genomes Project

The United Kingdom has opened up another front of its 100,000 Genomes Project. Having started off sequencing the genomes of people with rare diseases, the team behind the initiative are now ready to take aim at their other big target: cancer.

How openFDA's 'crazy collision' of Silicon Valley and federal culture is reshaping the regulator

Over the past two years the reputation of the IT department at the FDA has changed rapidly. Once best known for burning through CIOs and receiving slapdowns from the congressional watchdog, the FDA is now garnering plaudits for its embrace of agile and open development. This new way of thinking is central to--and to an extent responsible for--the recently unveiled precisionFDA initiative.

Mytrus makes electronic informed consent breakthrough in U.K.

The movement to shift informed consent in clinical trials from paper forms to electronic devices has notched up another victory. Mytrus and an unnamed top-10 pharma company made the advance by becoming the first organizations to win clearance to use e-consent in a trial in the United Kingdom.

Ginkgo Bioworks allies with Ajinomoto to expand into amino acid production

Ginkgo Bioworks has unveiled part of the expansion strategy it teased when it raised $45 million earlier this year.
MORE NEWS

From Our Sister Sites

FierceBiotech

Roche got a boost for one of its top late-stage prospects from the FDA today. The agency has handed out a breakthrough drug designation for its hemophilia A treatment ACE910 among patients with factor VIII inhibitors.

FierceBiotech

FiercePharma 's Carly Helfand and FierceBiotech 's Damian Garde discuss Valeant Pharmaceuticals' latest reclamation projects, the bad-cholesterol horse race between Sanofi and Amgen, and Novartis' apparent horror-movie aspirations. Peace to Wes Craven.